Structures of Aβ-Related Peptide−Monoclonal Antibody Complexes by Gardberg, Anna et al.
pubs.acs.org/Biochemistry Published on Web 04/22/2009 r 2009 American Chemical Society
5210 Biochemistry 2009, 48, 5210–5217
DOI: 10.1021/bi9001216
Structures of Aβ-Related Peptide-Monoclonal Antibody Complexes†,‡
Anna Gardberg,§,O Lezlee Dice, ),] Kathleen Pridgen,§ Jan Ko,^ Paul Patterson,^ Susan Ou,^ Ronald Wetzel,# and
Chris Dealwis*,4
§Department of Biochemistry and Cellular and Molecular Biology, University of Tennessee, Knoxville, Tennessee 37996,
)Graduate School of Medicine, University of Tennessee, Knoxville, Tennessee 37920, ^Division of Biology, California Institute of
Technology, Pasadena, California 91125, #Structural Biology Department and Pittsburgh Institute for Neurodegenerative Diseases,
Pittsburgh, Pennsylvania 15260, and 4Department of Pharmacology and Center for Proteomics, School of Medicine, Case Western
Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106 OCurrent address: Center for Structural Molecular Biology,
Oak Ridge National Laboratory, Oak Ridge, TN 37831-6142 ]Current address: Department of Molecular and
Structural Biochemistry, North Carolina State University, Raleigh, NC 27607
Received January 26, 2009; Revised Manuscript Received April 17, 2009
ABSTRACT: Passive immunotherapy (PI) is being explored as a potential therapeutic against Alzheimer’s
disease. The most promising antibodies (Abs) used in PI target the EFRH motif of the Aβ N-terminus.
The monoclonal anti-Aβ Ab PFA1 recognizes the EFRH epitope of Aβ. PFA1 has a high affinity for
Aβ fibrils and protofibrils (0.1 nM), as well as good affinity for Aβmonomers (20 nM). However, PFA1 binds
the toxicN-terminallymodified pyroglutamate peptide pyro-Glu3-Aβwith a 77-fold loss in affinity compared
to the WT Aβ(1-8). Furthermore, our earlier work illustrated PFA1’s potential for cross-reactivity. The
receptor tyrosine kinase Ror2, which plays a role in skeletal and bone formation, possesses the EFRH
sequence. PFA1 Fab binds the Ror2(518-525) peptide sequence REEFRHEA with a 3-fold enhancement
over WT Aβ(1-8). In this work, the crystal structures of the hybridoma-derived PFA1 Fab in complex
with pyro-Glu3-Aβ peptide and with a cross-reacting peptide from Ror2 have been determined at resolutions
of 1.95 and 2.7 A˚, respectively. As with wild-type Aβ, these peptides bind to the Fab via a combination
of charge- and shape-complementarity, hydrogen-bonding, and hydrophobic interactions. Comparison of
the structures of the four peptides Aβ(1-8), Grip1, pyro-Glu3-Aβ(3-8), and Ror2 in complex with PFA1
shows that the greatest conformational flexibility occurs at residues 2 to 3 and 8 of the peptide.
These structures provide a molecular basis of the specificity tolerance of PFA1 and its ability to recognize
Aβ N-terminal heterogeneity. The structures provide clues to improving mAb specificity and affinity for
pyroglutamate Aβ.
The deposition of amyloid aggregates of the amyloid β (Aβ)1
peptide is a hallmark of the underlying pathology of Alzheimer’s
disease (AD). The Aβ peptides, Aβ(1-40) and Aβ(1-42), are
degradation products of the amyloid precursor protein (APP)
resulting from the sequential proteolysis by the secretases, β and
γ, respectively (1).With two extra C-terminal residues, Aβ(1-42)
is considered the more toxic species found in amyloid deposits of
both humans and animalmodels ofAD.Thedirect immunization
of patientswithAβ fibrils in a phase II clinical trial was halted due
to the development of meningoencephalitis in 6% of the patients.
Passive immunotherapy (PI) where the humanized IgGs are
intravenously administered is potentially a safer treatment. At
least three mechanisms for the effectiveness of Aβ immunother-
apy in AD models have been proposed. Two mechanisms,
microglial activation (2, 3) and catalytic dissolution (4), require
that the antibody enter the brain. Another mechanism, some-
times called the peripheral sink hypothesis, does not have this
requirement. In the peripheral sink hypothesis (5), Abs bind to
Aβ in the blood and shift the distribution ofAβ between the brain
and the peripheral circulatory system, leading to a net efflux of
Aβ from the CNS to the peripheral circulatory system where it is
degraded (5). All three mechanisms require Ab binding to Aβ in
either monomer or aggregated forms. Since it is unclear which of
these mechanisms contributes to AD therapy, it can be argued
that the most appropriate Abs for therapy are those capable of
recognizing all assembly forms of Aβ peptides.
In a recent study, we demonstrated the molecular basis of
passive immunotherapy by determining the first X-ray crystal
structures of the N-terminal epitope of Aβ(1-8) (sequence
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DAEFRHDS) bound to the monoclonal antibodies (mAbs)
PFA1 and PFA2 (6). Briefly, the essential binding motif on Aβ
is the EFRH sequence at positions 3-6; this motif is recognized
by the Fabs’ complementarity determining regions, notably
a WWDDD region within heavy chain CDR2 in both PFA1
and PFA2.
PFA1 and PFA2 mAbs bind Aβ monomers, protofibrils, and
fibrils with nanomolar affinities (6) and hence show promise as
potential immunotherapy agents. Besides universal binding to all
known physical forms of Aβ(1-40) and Aβ(1-42), however, a
desired antibody or antibodies for treating AD should theoreti-
cally exhibit certain properties in their binding profile. First, there
are a variety of chemical degradation products of Aβ in vivo,
some of which are of equal or greater concern, vis a vis aggregate
formation and toxicity, than the intact Aβ sequence. Second,
since themAb’s binding epitope is a relatively short sequence, it is
possible that similar or identical sequences might exist elsewhere
in the proteome and exhibit cross-reactivity to the mAb with
potential toxic side effects. Thus, the ideal Ab for PI would
exhibit good specificity for all toxic and aggregating forms of Aβ
while at the same time avoiding high-affinity interactions with
other proteins.
The analysis of neuritic and vascular plaques shows that there
is substantial N-terminal heterogeneity of Aβ. For example, the
Aβ peptide can have its D residues at positions 1 and 7 racemized
or isomerized, and there are pyroglutaminyl (pyro-Glu) forms at
residues 3 and 11 (7-10). In fact, there is evidence to suggest the
major component of AD senile plaques is the N-terminal
modified Aβ beginning at E3, which is posttranslationally
modified to an N-terminal pyro-Glu(11-15). In some cases
pyro-Glu forms of Aβ at residues 3 (pyro-Glu3-Aβ(3-8)) and
11 (pyro-Glu11-Aβ) constitute more than 50% of the Aβ in
neuritic plaques (11). Interestingly, relative to age-matched
controls, AD sufferers have an abundance of pyro-Glu-Aβ in
their neuritic amyloid deposits, suggesting that pyro-Glu-Aβmay
play an important role in the onset of AD.
Supporting evidence for a role for pyro-Glu-Aβ peptides in
AD includes the following: (a) the pyro-Glu residue stabilizes the
amyloid peptides against degradation by aminopeptidases (16,
17); (b) pyro-Glu forms ofAβ appear in early stages of the disease
(18); (c) pyro-Glu-modified peptides form aggregates 250-fold
faster than WT Aβ (19); (d) pyro-Glu-Aβ peptides display an
enhanced cytotoxicity compared toWTAβ (9, 14); (e) based on in
vitro studies, pyro-Glu-modified Aβ peptides are potential seed-
ing species for Aβ aggregate formation in vivo (20, 21); and (f )
recently, inhibitors of the glutaminyl cyclase were shown to
reduce plaque burden dramatically and improve cognition in
AD mice (22). Unfortunately, given pyro-Glu3-Aβ’s potential
importance in disease etiology, we found that PFA1 Fab binds
pyro-Glu3-Aβwith amuch reduced affinity (77-fold difference in
Kd) when compared toAβ(1-8) (6).We would like to explore the
structural basis of this loss of affinity.
The shortness of the Aβ sequence epitope also raises possible
specificity issues. As a preliminary investigation of the specificity
of PFA1 and PFA2 with respect to the human genome, the WT
Aβ(2-7) peptide AEFRHD and mutants derived from proteins
listed in ref 6, AKFRHD, AEIRHD, AEFRSD, and REEF-
RHEA, were synthesized, and their affinity for the two Fab
fragments was determined by surface plasmon resonance (SPR)
(Table 1). AEIRHD and AEFRSD showed no measurable
binding to PFA1 and PFA2. However, we found that PFA1
Fab binds toAKFRHD (a sequence found in glutamate receptor
interacting protein 1 (GRIP1)) with an affinity 28 times lower
than to AEFRHD (6). Perhaps more significantly, the peptide
sequence REEFRHEA, found in the cytosolic tyrosine kinase
domain of human receptor-related neurotrophic tyrosine kin-
ase (Ror2(518-525)), actually binds to PFA1 and PFA2 with
approximately twice the affinity of the WT Aβ(2-7) peptide
AEFRHD. Interestingly, Ror2 plays a role in bone formation
(23), while Grip1 is responsible for maintaining the plasticity
ofR-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)
glutamate receptors by PDZ domain interactions (24, 25).
Here we report the crystal structures of PFA1 complexed with
pyro-Glu3-Aβ(3-8) and Ror2(518-525). These structures pro-
vide the molecular details that should make possible the optimi-
zation of mAb structure to appropriately adjust its binding
affinities for these peptides.
MATERIALS AND METHODS
Protein Production and Purification. The hybridoma
production of PFA1 and its purification and Fab generation
were described previously(6).
Crystallization, Data Collection, and Processing. Crystal
screening was performed with the PEGs Suite (QIAGEN) using
the PHOENIX crystallization robot (Art Robbins Instruments).
The PFA1-Ror2(518-525) complex and the PFA1-pyro-Glu3-
Aβ(3-8) complex were crystallized using the sitting drop vapor
diffusion method. Cocrystals of the PFA1-Ror2(518-525) pep-
tide complex appeared in a solution containing 0.2 M LiCl and
20%w/v PEG3350without a buffer. The cocrystals of the PFA1-
pyro-Glu3-Aβ(3-8) complex were grown in a solution consisting
of 0.1M Tris-HCl, pH 8.5, and 25% (w/v) PEG2000-MME. For
X-ray data collection, all crystals were harvested into a cryopro-
tectant solution. For the PFA1-Ror2(518-525) cocrystals, this
consisted of 0.2 M LiCl, 25% PEG3350, and 20% glycerol. The
PFA1-pyro-Glu3-Aβ(3-8) cocrystals were cryoprotected using
0.1 M Tris-HCl, pH 8.5, 28% PEG2000-MME, and 20%
glycerol. Crystals were flash-frozen in liquid nitrogen. All dif-
fraction data were collected at the Advanced Photon Source,
beamline 14BMC (BIOCARS-CAT), with a Q315 detector. The
oscillation range was 0-250 in 0.5 increments for the PFA1-
Ror2(518-525) cocrystals and was 0-190 in 0.5 increments for
the PFA1-pyro-Glu3-Aβ(3-8) cocrystals. Data for both of the
cocrystals were indexed, integrated, and scaled using the
HKL2000 package (26). Although the data for PFA1 complexed
with pyro-Glu is 92% complete at 2.2 A˚ resolution, the data can
be processed to 1.95 A˚ resolution with greater than 50%
completeness in the last shell. The PFA1-Ror2 complex dif-
fracted to 2.7 A˚ resolution with 85% completeness. The lack
Table 1: Alignment of Peptide Sequences Relevant to This Work and Kd
Measurements for Peptide Binding to the PFA1 Faba
protein/peptide sequence
Kd (nM)
measurements
from SPR
Aβ(1-40) WT (“WT”)
Aβ(2-7) WT
DAEFRDHS...
AEFRHD
39.0
60
pyro-Glu3-Aβ(3-8) pEFRHDS 3000
Ror2(518-525) REEFRHEA 24
Grip1(110-115) AKFRHD 3400
position 4 mutant AEIRHD no binding
position 6 mutant AEFRSD no binding
aTaken from ref 6.
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of >90% completeness can be attributed to the large blind spot
region encountered in the P1 space group.
Molecular Replacement and Structure Refinement. The
structures were solved by molecular replacement using the
constant (CL + CH1) and variable portions of PFA1 (PDB
code 1IPU) separately using MOLREP (27). Protein rebuilding,
including water picking, was performed using Coot (28). Refine-
ment was conducted using Refmac5 (29), and the structures were
validated with SFCHECK (30), PROCHECK (31), and MOL-
PROBITY (32).As reported byPROCHECK, 99.7%and 99.5%
of the residues lie in the allowed regions of the Ramachandran
plot for PFA1-pyro-Glu3-Aβ(3-8) and PFA1-Ror2(518-525)
complex structures, respectively. Data collection and refinement
statistics appear in Table 2. Calculation of buried surface area
was carried out using AREAIMOL (33, 34) with a 1.4 A˚ probe
radius.
RESULTS
To explore the binding mode of pyro-Glu3-F-R-H-D-S (pyro-
Glu3-Aβ(3-8)) peptide to themAbPFA1, aswell as the potential
for cross-reactivity with the protein Ror2, we determined the
three-dimensional X-ray structures of the two binary cocom-
plexes PFA1-Fab-pyro-Glu3-Aβ(3-8) and PFA1-Fab-Ror2
(518-525) to 1.9 and 2.7 A˚, respectively (see Table 2 for peptide
sequences). Both structures have reasonable refinement statistics
as shown in Table 2, and they are isomorphous to the apo PFA1
structure (6). The 2Fo - Fc difference Fourier electron density
map clearly defines the first five residues of the pyro-Glu3-Aβ-
(3-8) and the EFRHEA sequence of the Ror2(518-525) of the
two structures (Figure 1 and Table 1), and the electron density
for the complementarity determining regions (CDRs) is readily
traced. The antigen-binding site, which lies in a cleft between
the light- and heavy-chain variable domains, is formed by
four of the six CDRs: CDR-L1 (QSIVHSNGNTY), CDR-L3
(FQGSHVPLTF), CDR-H2 (IW-WDDDR), and CDR-H3
(VRRAHTTVLGDWFAY). The residues in bold-face type
directly interact with the antigen.
Overall, the pyro-Glu3-Aβ(3-8) peptide adopts a slightly
extended coil conformation that is stabilized by hydrogen bonds,
van der Waals, and ion pair interactions (see Figure 2A). The
crucial mAb-binding epitope is the 3EFRH6 at the N-terminus of
Aβ, which we previously showed to be extremely sensitive to
mutations. Mutating any single residue in this epitope to alanine
essentially abolishes binding (6). The (FR) of the 3EFRH6 motif
makes interactions with a WWDDD motif belonging to CDR-
H2, similar to that observed in the Aβ WT complex.
The Glu to pyro-Glu substitution at position 3 has a drastic
effect on mAb binding (6). However, the CR rms deviation for
residues 3-8 between the WT Aβ and pyro-Glu3-Aβ(3-8) is
only 0.24 A˚. This is not surprising as the main-chain and side-
chain conformations between the two peptides are extremely
conserved beyond residue 3 (see Figure 2A). In fact, the main-
chain conformation of all the peptide complexes determined by
our laboratory is extremely conserved as reflected by their small
rms deviations (see Table 3 and Figure 2C). The greatest
structural difference between WT Aβ(1-8) and pyro-Glu3-
Aβ(3-8) is found at position 3. Interestingly, the pyroglutaminyl
ring occupies overlapping space with the E3 side chain ofWTAβ
(see Figure 2A). Consequently, this places the pyro-Glu3 amide
nitrogen within hydrogen-bonding distance of the carbonyl of
Table 2: Crystallographic Data Collection and Refinement Parameters
PFA1-Ror2
(518-525)
PFA1-pyro-
Glu3-Aβ(3-8)
Data Collection
space group P1 P1
cell dimensions
a, b, c (A˚) 41.6, 42.6, 58.7 41.7, 42.7, 58.6
R, β, γ (deg) 96.1, 93.6, 91.7 96.1, 93.8, 91.7
resolution (A˚)
(last shell)
30-2.7 (2.8-2.7) 35-1.9 (2.02-1.95)
Rsym 0.083 (0.222) 0.049 (0.284)
I/Iσ 12.8 (2.8) 17.5 (2.2)
completeness (%) 85.0 (49.9) 86.4 (54.2)
redundancy 2.3 (1.6) 1.8 (1.5)
Refinement
resolution (A˚) 2.7 1.9
no. of reflections 8780 23906
TLS groups 5 0
Rwork/Rfree (%) 17.7/24.8 20.4/25.6
no. of atoms
protein (non-H) 3421 3495
ligand/ion 0 6 (glycerol)
water 23 113
B-factors (A˚2) 32 35
bound peptide 40 52
ligand/ion none 41 (glycerol)
water 30 40
rmsd bond lengths (A˚) 0.010 0.010
rmsd bond angles (deg) 1.2 1.3
Ramachandran
allowed region (%)
99.5 99.7
PDB code 3EYU 3EYS
FIGURE 1: Stereoviewof 2Fo-FcmapsofPFA1binding to the pyro-
Glu3-Aβ(3-8) peptide (a) and the Ror2(518-525) (b). The maps
were contoured at 1.1σ (within 2 A˚ of the peptide). Numbering
scheme is that of Aβ(1-8) WT (see Table 1).
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S97, an interaction that theWTAβ cannotmake.However, while
the carbonyl oxygen of pyro-Glu3 occupies a position merely
1.9 A˚ away from that of the Oε1 atom of the unmodified Aβ E3
side chain, this is still too far away to form compensatory
hydrogen bonds; the nearest hydrogen-bonding donor to the
carbonyl oxygen atomof pyro-Glu3 is 4 A˚ away. The carboxylate
side chain of E3 in WT Aβ forms two hydrogen bonds to the
amide of the main chain and the hydroxyl group of LC S32. The
distance between the amide of LC S32 and the Oε1 of E3 is 2.6 A˚,
while the distance between the hydroxyl of S32 and the Oε2 of E3
is 2.8 A˚. In the PFA1-pyro-Glu3-Aβ(3-8) structure, pyro-Glu3
does not form these two important hydrogen bonds. Instead, the
oxygen that is attached to the pyroglutaminyl ring is almost 4.7 A˚
away from the amide nitrogen of S32. Furthermore, E3 makes
some long-range (<5 A˚) ion pair interactions with the LC H98
side chain. A complete list of pyro-Glu3 interactions with PFA1
is compared with those of the WT Aβ(1-8) in Supporting
Information Table 1A,B.
Although there are sequence differences at four positions
between WT Aβ(1-8) and the Ror2(518-525) (Table 1), the
Ror2(518-525) binds PFA1 similarly to the WT Aβ(1-8). The
rmsd between the CR atoms is 0.3 A˚ (Table 3). The greatest dif-
ferences between the two peptide structures occur at E3, at posi-
tion 7 where the WT Aβ residue D7 is substituted by E in Ror2
(518-525), and at the C-terminus, where S8 of the WT Aβ is
replaced by A in Ror2(518-525) (Table 1 and Figures 2B and
3A). The E3 side chain adopts a different conformation in theWT
Aβ; the carboxylate side chain hydrogen bonds with the hydroxyl
of LC S27E, while in Ror2(518-525) the E3 side chain hydrogen
bonds with the imidazole side chain of LCH93. Interestingly, the
differingE3 interactions between the two peptides appear to result
from the SfA substitution at position 8 in Ror2(518-525) that
leads to a chain of events spanning nearly an 8 A˚ distance. First,
the substitution causes a main-chain conformational difference
that places the carboxyl terminus of Ror2(518-525) further from
LC S27E, abrogating the formation of a water-mediated second
sphere hydrogen bond between the COOH and LC S27E
observed in the WT Aβ complex (see Figure 3A). Second, the
Ror2(518-525)’s COOHgroup is positioned such that it is unable
to stabilize the aforementioned watermolecule. Indeed, we do not
observe electron density for a water molecule near this position in
the PFA1- Ror2(518-525) complex structure. Third, the absence
of the water molecule prevents the formation of the hydrogen
bond between the water and E3 that is observed in WT Aβ,
resulting in side-chain conformational flexibility of Ror2(518-
525)’s E3 which finds a new hydrogen bond partner in LC H93.
These observations suggest that there is cross-talk between the
binding sites 3 and 8 (Figures 2B and 3A). Also, the substitution
of D to E at position 7 results in a slight change in the main-chain
conformation between WT Aβ and Ror2(518-525) (Figure 2B).
FIGURE 2: Comparison of Aβ and related peptide structures. Stereo-
view of the overlay ofAβ(1-8)WTpeptide (green) with (a) pyropep-
tide (blue) and (b) Ror2(518-525) (pink). The PFA1 residues are
drawn with thinner bonds and similarly color-coded, save that the
light chain is shown in a paler shade and the heavy chain is shown in
a darker shade. The numbering scheme is that of Aβ(1-8) WT. The
WWDDDmotif appears in the lower left corner of (a) and (b); D57
points away from the bound peptide and does not bind to it.
(c) Superposition of Aβ-related peptide structures demonstrat-
ing coupled position changes (“cross-talk”) of residues 3 and 8: Aβ-
(1-8) (cyan), Grip1(110-115) (orange), pyro-Glu3-Aβ (white), and
Ror2(518-525) (purple) bound to PFA1. The side chains aremarked
P2-P8, where P stands for the peptide position.
Table 3: Root Mean Square Differences (RMSDs) for the CDRs of Five PFA1 Structures
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This, combined with the larger E side chain of Ror2(518-525),
positions its carboxyl group further away from the imidazole
hydrogen bond donor ofHCH102, resulting in a longer hydrogen
bond (3.4 A˚ for PFA1-Ror2(518-525) versus 2.6 A˚ for PFA1-
Aβ(1-8)) between D7 of the bound peptide and H-H102 of
PFA1. However, compared to the WT Aβ, the larger E7 side
chain of Ror2(518-525) makes a much shorter intramolecular
ion pair interaction with the guanidinium group of R5 (4.7 versus
5.7 A˚) belonging to the EFRHmotif. A complete list of the Ror2
(518-525) peptide’s interactions with PFA1 is compared with
those of theWTAβ(1-8) in Supporting Information Table 1B,C.
PFA1 binds Ror2(518-525) with an approximately 3-fold
improved affinity compared to WT Aβ.
DISCUSSION
To understand why the pyro-Glu modification lowers affinity
to PFA1, it is helpful to review the core binding for the WT Aβ
peptide. The E3 side chain of the Aβ peptide makes important
hydrogen bonds with the antibody, its only charge complemen-
tarity is with LC H31’s side chain, which has an average ∼10%
charge at physiological pH, so the mAb does not exploit charge
complementarity to significantly stabilize E3 (Figure 2A). The
Aβ peptide residues F4, R5, and H6 make more specific inter-
actions, however. F4 sits in a complementarily shaped hydro-
phobic pocket made up of heavy chain residues W47, H50, W52,
and F100(E) (Kabat numbering) and light chain residuesV94 and
L96 (Figure 4A). Arginine 5 fits neatly into a shallow cavity
consisting of heavy chain residues D54 and D56 for charge
complementarity, with residue H97 providing π-overlap for the
FIGURE 3: Superposition of Aβ and related structures. (a) Aβ(1-8)
(green) andRor2(518-525) (purple) bound to PFA1 (PFA1 residues
are drawn in the same colors corresponding to each peptide).
(b) Superposition of PFA1 (CDRs and peptide drawn in green) and
WO2 (CDRs in cyan and peptide drawn in red) CDRs. (c) Compar-
ison of PFA1-Aβ(1-8) (peptide and Fab residues are in green) and
WO2-Aβ(1-16) (peptide drawn in red and the Fab residues are in
cyan) binding sites. One hydrogen bond is shown in dashed lines
between HC Y52 of WO2 and the amide of R3 of the Aβ(1-16) to
highlight the CDR sequence difference at HCY52. The Fab residues
are labeled according to the PFA1 sequence and numbered according
to the Kabat convention (http://www.biochem.ucl.ac.uk/∼martin/
abs/GeneralInfo.html).
FIGURE 4: Electrostatics of binding: (a) the electrostatic potential
surface of PFA1 with bound Aβ(1-8)peptide, (b) with bound pyro-
Glu3-peptide, and (c) Ror2(518-525). Blue represents positive
charge, red indicates negative charge, and the uncharged portions
are shown in white. Each of the peptides is drawn with carbon
(yellow), nitrogen (blue), and oxygen (red). The numbering scheme
is that of Aβ(1-8) WT.
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guanidinium group and with residue W52 providing a hydro-
phobic patch near the aliphatic atoms of R5’s side chain. Finally,
H6points into a complementary pocket, withπ-overlap provided
by light chain residue Y32. H6 forms hydrogen bonds to light
chain residue G91 and to heavy chain residue D100(C); light
chain residue H27(D) also contributes to the shape of this cavity.
The full impact of the pyro-Glu3 modification to PFA1 binding
can be observed when comparing electrostatic binding surfaces
(Figure 4A,B). Binding energy of protein-protein or protein-
ligand can be expressed as a linear combination of the differences
in polar and apolar solvent-accessible surface areas between
those states (35).The pyro-Glu3-Aβ(3-8) peptide buries 432.9 A˚2
of the antibody surface when binding to PFA1, which is some 60
A˚2 less than that of theWTAβ. The difference in SA is ultimately
attributable to the reduced length of the pyro-Glu3-Aβ(3-8)
peptide (6 residues) compared toWTAβ (8 residues). The PFA1-
pyro-Glu3-Aβ(3-8) cocrystal structure reveals that the loss of
binding of pyro-Glu3-Aβ to PFA1 is in part due to the loss of
crucial hydrogen bonds and long-range ion pair interactions with
E3. It is also due to the loss of buried SA caused by the shorter
pyro-Glu3-Aβ(3-8) peptide compared to WT Aβ peptide.
As noted before (19), the following factors may contribute to
pyro-Glu-Aβ peptides’ acceleration of fibril forming kinetics.
First, the pyro-Glu(3-40)-Aβ lacks a chargedN-terminal group,
making it more hydrophobic (depicted in Figure 4). Second,
it has been noted that the capped N-terminus resulting from
cyclization reduces Aβ’s propensity to form intramolecular
antiparallel β-sheets (19). This is particularly important, as fiber
diffraction and solid-state NMR data have shown the fibrils are
composed of intermolecular, in-register, parallel β-sheets formed
by hydrogen bonding betweenAβmonomers (36, 37).Moreover,
the introduction of a lactam modification that restrains rota-
tion of the peptide bond promotes fibrilogenesis by favoring a
conformation prone to aggregation (38). Finally, unlike other
N-terminal modifications, which are extremely unstable, the
pyro-Glu residue stabilizes the Aβ peptide against degradation
by aminopeptidases (16, 17). Hence, its stability, hydrophobicity,
and structure make it a perfect seed for fibrilogenesis and, thus, a
good target for mAb therapy.
Recently, two other related structures have been reported
(39, 40). The first structure is of Aβ(17-36) in complex with an
affibody adopting a β-conformation (39). However, as the
N-terminus of Aβ is absent in this structure, we are unable to
do a comparison with our PFA1-Aβ(1-8) complex. The second
structure is that of Aβ(1-16) in complex with the Fab fragment
of the mAbWO2 (40). Although residues 1-16 of Aβ were used
in the cocrystallization experiment, only residues 1-8 of Aβwere
observed in the electron density maps. Comparison of the PFA1-
Aβ(1-8) with the WO2-Fab-Aβ(1-16) structure reveals that the
greatest conformational differences between the two Fabs occur
at the twoCDRsH2 andH3 that interact with residues 7 and 8 of
the Aβ peptide (see Figure 3b,c). The Aβ(1-8) peptide confor-
mations bound to PFA1 and WO2 are extremely well conserved
between residues 1-6 (see Figure 3c). The FR residues of the
EFRH motif in the WO2Fab-Aβ(1-16) structure, as in our
PFA1-Aβ(1-8) structure, interact with the CDRH2 residues
52-56; in PFA1-Aβ(1-8), this segment comprises a WWDDD
motif. This motif is conserved in WO2, except that in the WO2
mAb, HC W52 is substituted by Y. The side-chain hydroxyl of
HC Y52 in WO2 makes a hydrogen bond with the main-chain
amide of R5 of Aβ, an interaction not observed in the PFA1-
Aβ(1-8) complex. Residues D7 and S8 of the Aβ(1-8) peptide
show the greatest main-chain conformational difference between
the PFA1-Aβ(1-8) and the WO1Fab-Aβ(1-16) structure. One
reason for this can be attributed to the previously mentioned
chemical and conformational difference at CDRH3 between the
two structures: we observe D7 of Aβ(1-8) in the WO1 complex
occupying a sterically overlapping position with the imidazole
side chain of HC H97 of PFA1 (Figure 3b,c). For these reasons,
the Fab contact surface of Aβ(7-8) differs between the two
complexes. In theWO2-Fab-Aβ(1-16) complex, residues 7 and 8
contact HC Y100B; in PFA1, they interact instead with HC T98
andHCE100C. The E100C does not have a spatially overlapping
residue in PFA1 due to the conformational differences in loop
CDRH3 between the twomAbs. Other substitutions between the
PFA1 and WO2 include HC S58 f R and LC H93f L.
The EFRH motif of the Aβ N-terminus (comprising of
residues 3-6) is the dominant binding epitope for PFA1 and
for the recently reported IgG,WO2.The examination of theRor2
(518-525)-PFA1 complex reveals that the Fab’s enhanced
affinity for Ror2(518-525) when compared to Aβ is likely due
to an increased number of electrostatic interactions as well as
more favorable intramolecular interactions, possibly stabiliz-
ing the peptide conformation. Although the Ror2(518-525)
sequence is found in the (predicted) cytosolic portion of the
protein, Tampellini et al. have shown evidence for anti-Aβ mAb
internalization(41, 42). Hence, its enhanced affinity for PFA1
does strikingly illustrate the risk of cross-reactivity that stems
from the short EFRH epitope. Based on our four PFA1-peptide
complex structures (Table 1), the greatest variation in the peptide
conformations occurs at the N-terminus (positions 2 and 3) and
at position 8 at the C-terminus, and less so at position 7
(Figure 2C). Structurally, the FRH main-chain and side-chain
conformations are extremely conserved.Hence, to ensure binding
to N-terminal variants of Aβ such as pyro-Glu3-Aβ while
improving the specificity of PFA1-derived mAbs toward the
N-terminus of Aβ, mutations to PFA1 will have to concentrate
on optimizing interactions at subsites 7 and beyond. Two such
possibilities that we have modeled are to mutate HC 98 to K, or
to mutate HC 100 (Kabat numbering) from V to R or K,
introducing charge complementarity to enhance binding to D7
of Aβ. To enhance affinity to the N-terminus of the pyro-Glu3-
Aβ peptide, mutatingmAb residue LC S27EfQwould put that
side chain in a position to form a hydrogen bond with the lactam
carbonyl oxygen atom of peptide residue pyro-Glu3. While these
mutations might not help to distinguish Aβ from Ror2 as such
(Ror2 is E7 at that position), they could nonetheless address a
general problem with most anti-Aβ mAbs: the short length of
immunodominant EFRH binding epitope.
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